{"transactions":[{"id":953798,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CEO"}}],"security":"2020 Performance Stock Units","published_at":"2026-01-05T22:53:17.000Z","date":"2025-12-31","kind":"exercise","planned":false,"acquired":false,"shares":28570,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance restricted stock unit (\"PSU\") represents a contingent right to receive one share of Company stock. These PSUs were earned during the applicable five-year performance period and vested on December 31, 2025 but remain subject to a mandatory holding period of three years after vesting, which ends early upon the reporting person's death or disability or a change in control of the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each performance restricted stock unit (\"PSU\") represents a contingent right to receive one share of Company stock. These PSUs were earned during the applicable five-year performance period and vested on December 31, 2025 but remain subject to a mandatory holding period of three years after vesting, which ends early upon the reporting person's death or disability or a change in control of the Company."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each performance restricted stock unit (\"PSU\") represents a contingent right to receive one share of Company stock. These PSUs were earned during the applicable five-year performance period and vested on December 31, 2025 but remain subject to a mandatory holding period of three years after vesting, which ends early upon the reporting person's death or disability or a change in control of the Company."}],"balance_after":595077,"derivative":{"underlying":"Common Stock","underlying_shares":28570},"source":{"system":"sec-edgar","filing":"0001218629-26-000002","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/872589/000121862926000002/edgardoc.xml","form_type":"4"}},{"id":953797,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CEO"}}],"security":"Common Stock","published_at":"2026-01-05T22:53:17.000Z","date":"2025-12-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":28570,"price":772.09,"value":22058611.3,"ownership":{"direct":true},"balance_after":214523,"source":{"system":"sec-edgar","filing":"0001218629-26-000002","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000121862926000002/edgardoc.xml","form_type":"4"}},{"id":953796,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CEO"}}],"security":"Common Stock","published_at":"2026-01-05T22:53:17.000Z","date":"2025-12-31","kind":"exercise","planned":false,"acquired":true,"shares":28570,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":243093,"source":{"system":"sec-edgar","filing":"0001218629-26-000002","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000121862926000002/edgardoc.xml","form_type":"4"}},{"id":973335,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CEO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2025-12-11T21:23:04.000Z","date":"2025-12-09","kind":"exercise","planned":false,"acquired":false,"shares":172723,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option award vested in four equal annual installments, commencing one year after the date of grant."}],"balance_after":0,"derivative":{"exercise_price":555.67,"expiration_date":"2025-12-16","underlying":"Common Stock","underlying_shares":172723},"source":{"system":"sec-edgar","filing":"0001218629-25-000006","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/872589/000121862925000006/edgardoc.xml","form_type":"4"}},{"id":973334,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CEO"}}],"security":"Common Stock","published_at":"2025-12-11T21:23:04.000Z","date":"2025-12-09","kind":"tax_withholding","planned":false,"acquired":false,"shares":155145,"price":701.51,"value":108835768.95,"ownership":{"direct":true},"balance_after":214523,"source":{"system":"sec-edgar","filing":"0001218629-25-000006","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000121862925000006/edgardoc.xml","form_type":"4"}},{"id":973333,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CEO"}}],"security":"Common Stock","published_at":"2025-12-11T21:23:04.000Z","date":"2025-12-09","kind":"exercise","planned":false,"acquired":true,"shares":172723,"price":555.67,"value":95976989.41,"ownership":{"direct":true},"balance_after":369668,"source":{"system":"sec-edgar","filing":"0001218629-25-000006","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000121862925000006/edgardoc.xml","form_type":"4"}},{"id":1481357,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CEO"}}],"security":"Class A Stock","published_at":"2024-06-13T20:01:19.000Z","date":"2024-06-12","kind":"exercise","planned":true,"acquired":false,"shares":1000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"by Trust for Son"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Class A Stock of the Company converts to common stock of the Company on a one-to-one basis upon certain events or upon election of the shareholder."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 5, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"These shares of Class A Stock are presently convertible and such conversion feature does not expire."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"These shares of Class A Stock are presently convertible and such conversion feature does not expire."}],"balance_after":14775,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1000},"source":{"system":"sec-edgar","filing":"0001104659-24-071247","document":"tm2417175-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/872589/000110465924071247/tm2417175-1_4seq1.xml","form_type":"4"}},{"id":1481356,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CEO"}}],"security":"Common Stock","published_at":"2024-06-13T20:01:19.000Z","date":"2024-06-12","kind":"sale","planned":true,"acquired":false,"shares":1000,"price":1025.27,"value":1025270.0,"ownership":{"direct":false,"nature":"by Trust for Son"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 5, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents volume-weighted average price of sales of 1,000 shares of Company stock on June 12, 2024 at prices ranging from $1,025.00 to $1,025.55. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 12, 2024 at each separate price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-24-071247","document":"tm2417175-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/872589/000110465924071247/tm2417175-1_4seq1.xml","form_type":"4"}},{"id":1481355,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CEO"}}],"security":"Common Stock","published_at":"2024-06-13T20:01:19.000Z","date":"2024-06-12","kind":"exercise","planned":true,"acquired":true,"shares":1000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"by Trust for Son"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 5, 2024."}],"balance_after":1000,"source":{"system":"sec-edgar","filing":"0001104659-24-071247","document":"tm2417175-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/872589/000110465924071247/tm2417175-1_4seq1.xml","form_type":"4"}},{"id":1481354,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CEO"}}],"security":"Common Stock","published_at":"2024-06-13T20:01:19.000Z","date":"2024-06-12","kind":"sale","planned":true,"acquired":false,"shares":270,"price":1016.62,"value":274487.4,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 5, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents volume-weighted average price of sales of 270 shares of Company stock on June 12, 2024 at prices ranging from $1,016.10 to $1,016.80. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 12, 2024 at each separate price."}],"balance_after":39985,"source":{"system":"sec-edgar","filing":"0001104659-24-071247","document":"tm2417175-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/872589/000110465924071247/tm2417175-1_4seq1.xml","form_type":"4"}},{"id":1481353,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CEO"}}],"security":"Common Stock","published_at":"2024-06-13T20:01:19.000Z","date":"2024-06-12","kind":"sale","planned":true,"acquired":false,"shares":14879,"price":1015.3,"value":15106648.7,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 5, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents volume-weighted average price of sales of 14,879 shares of Company stock on June 12, 2024 at prices ranging from $1,015.00 to $1,015.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 12, 2024 at each separate price."}],"balance_after":40255,"source":{"system":"sec-edgar","filing":"0001104659-24-071247","document":"tm2417175-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/872589/000110465924071247/tm2417175-1_4seq1.xml","form_type":"4"}},{"id":1481352,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CEO"}}],"security":"Common Stock","published_at":"2024-06-13T20:01:19.000Z","date":"2024-06-11","kind":"sale","planned":true,"acquired":false,"shares":1743,"price":1016.04,"value":1770957.72,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 5, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents volume-weighted average price of sales of 1,743 shares of Company stock on June 11, 2024 at prices ranging from $1,016.04 to $1,016.10. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 11, 2024 at each separate price."}],"balance_after":55134,"source":{"system":"sec-edgar","filing":"0001104659-24-071247","document":"tm2417175-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/872589/000110465924071247/tm2417175-1_4seq1.xml","form_type":"4"}},{"id":1481351,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CEO"}}],"security":"Common Stock","published_at":"2024-06-13T20:01:19.000Z","date":"2024-06-11","kind":"sale","planned":true,"acquired":false,"shares":7321,"price":1015.28,"value":7432864.88,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 5, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents volume-weighted average price of sales of 7,321 shares of common stock of Regeneron Pharmaceuticals, Inc. (the \"Company\") on June 11, 2024 at prices ranging from $1,015.00 to $1,015.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 11, 2024 at each separate price."}],"balance_after":56877,"source":{"system":"sec-edgar","filing":"0001104659-24-071247","document":"tm2417175-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000110465924071247/tm2417175-1_4seq1.xml","form_type":"4"}},{"id":1485650,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CEO"}}],"security":"Common Stock","published_at":"2024-06-10T20:03:26.000Z","date":"2024-06-06","kind":"sale","planned":true,"acquired":false,"shares":787,"price":1015.02,"value":798820.74,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 5, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents volume-weighted average price of sales of 787 shares of Company stock on June 6, 2024 at prices ranging from $1,015.00 to $1,015.25. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 6, 2024 at each separate price."}],"balance_after":64198,"source":{"system":"sec-edgar","filing":"0001883850-24-000029","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385024000029/edgardoc.xml","form_type":"4"}},{"id":1512836,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CEO"}}],"security":"Common Stock","published_at":"2024-05-17T21:57:52.000Z","date":"2024-05-17","kind":"sale","planned":true,"acquired":false,"shares":143,"price":980.07,"value":140150.01,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 5, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents volume-weighted average price of sales of 143 shares of Company stock on May 17, 2024 at prices ranging from $980.01 to $980.20. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 17, 2024 at each separate price."}],"balance_after":466877,"source":{"system":"sec-edgar","filing":"0001883850-24-000025","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385024000025/edgardoc.xml","form_type":"4"}},{"id":1512835,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CEO"}}],"security":"Common Stock","published_at":"2024-05-17T21:57:52.000Z","date":"2024-05-17","kind":"sale","planned":true,"acquired":false,"shares":22687,"price":979.22,"value":22215564.14,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 5, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents volume-weighted average price of sales of 22,687 shares of Company stock on May 17, 2024 at prices ranging from $979.00 to $979.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 17, 2024 at each separate price."}],"balance_after":467020,"source":{"system":"sec-edgar","filing":"0001883850-24-000025","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385024000025/edgardoc.xml","form_type":"4"}},{"id":1516593,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CEO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2024-05-15T22:10:22.000Z","date":"2024-05-13","kind":"exercise","planned":true,"acquired":false,"shares":203204,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 5, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F14","text":"The stock option award vests in four equal annual installments, commencing one year after the date of grant."}],"balance_after":0,"derivative":{"exercise_price":399.66,"expiration_date":"2024-12-16","underlying":"Common Stock","underlying_shares":203204},"source":{"system":"sec-edgar","filing":"0001883850-24-000022","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385024000022/edgardoc.xml","form_type":"4"}},{"id":1516592,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CEO"}}],"security":"Common Stock","published_at":"2024-05-15T22:10:22.000Z","date":"2024-05-15","kind":"sale","planned":true,"acquired":false,"shares":299,"price":988.76,"value":295639.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 5, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"Represents volume-weighted average price of sales of 299 shares of Company stock on May 15, 2024 at prices ranging from $988.00 to $988.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price."}],"balance_after":397259,"source":{"system":"sec-edgar","filing":"0001883850-24-000022","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385024000022/edgardoc.xml","form_type":"4"}},{"id":1516591,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CEO"}}],"security":"Common Stock","published_at":"2024-05-15T22:10:22.000Z","date":"2024-05-15","kind":"sale","planned":true,"acquired":false,"shares":228,"price":987.46,"value":225140.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 5, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"Represents volume-weighted average price of sales of 228 shares of Company stock on May 15, 2024 at prices ranging from $987.31 to $987.63. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price."}],"balance_after":397558,"source":{"system":"sec-edgar","filing":"0001883850-24-000022","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385024000022/edgardoc.xml","form_type":"4"}},{"id":1516590,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CEO"}}],"security":"Common Stock","published_at":"2024-05-15T22:10:22.000Z","date":"2024-05-15","kind":"sale","planned":true,"acquired":false,"shares":103,"price":986.57,"value":101616.71,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 5, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"Represents volume-weighted average price of sales of 103 shares of Company stock on May 15, 2024 at prices ranging from $986.37 to $986.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price."}],"balance_after":397786,"source":{"system":"sec-edgar","filing":"0001883850-24-000022","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385024000022/edgardoc.xml","form_type":"4"}},{"id":1516589,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CEO"}}],"security":"Common Stock","published_at":"2024-05-15T22:10:22.000Z","date":"2024-05-15","kind":"sale","planned":true,"acquired":false,"shares":281,"price":985.72,"value":276987.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 5, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Represents volume-weighted average price of sales of 281 shares of Company stock on May 15, 2024 at prices ranging from $985.13 to $985.84. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price."}],"balance_after":397889,"source":{"system":"sec-edgar","filing":"0001883850-24-000022","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385024000022/edgardoc.xml","form_type":"4"}},{"id":1516588,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CEO"}}],"security":"Common Stock","published_at":"2024-05-15T22:10:22.000Z","date":"2024-05-15","kind":"sale","planned":true,"acquired":false,"shares":305,"price":984,"value":300120.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 5, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Represents volume-weighted average price of sales of 305 shares of Company stock on May 15, 2024 at prices ranging from $984.00 to $984.02. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price."}],"balance_after":398170,"source":{"system":"sec-edgar","filing":"0001883850-24-000022","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385024000022/edgardoc.xml","form_type":"4"}},{"id":1516587,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CEO"}}],"security":"Common Stock","published_at":"2024-05-15T22:10:22.000Z","date":"2024-05-15","kind":"sale","planned":true,"acquired":false,"shares":250,"price":983.91,"value":245977.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 5, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Represents volume-weighted average price of sales of 250 shares of Company stock on May 15, 2024 at prices ranging from $983.82 to $983.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price."}],"balance_after":398475,"source":{"system":"sec-edgar","filing":"0001883850-24-000022","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385024000022/edgardoc.xml","form_type":"4"}},{"id":1516586,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CEO"}}],"security":"Common Stock","published_at":"2024-05-15T22:10:22.000Z","date":"2024-05-15","kind":"sale","planned":true,"acquired":false,"shares":235,"price":982.66,"value":230925.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 5, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents volume-weighted average price of sales of 235 shares of Company stock on May 15, 2024 at prices ranging from $982.31 to $982.68. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price."}],"balance_after":398725,"source":{"system":"sec-edgar","filing":"0001883850-24-000022","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385024000022/edgardoc.xml","form_type":"4"}},{"id":1516585,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CEO"}}],"security":"Common Stock","published_at":"2024-05-15T22:10:22.000Z","date":"2024-05-15","kind":"sale","planned":true,"acquired":false,"shares":1081,"price":981.5,"value":1061001.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 5, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents volume-weighted average price of sales of 1,081 shares of Company stock on May 15, 2024 at prices ranging from $981.09 to $981.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price."}],"balance_after":398960,"source":{"system":"sec-edgar","filing":"0001883850-24-000022","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385024000022/edgardoc.xml","form_type":"4"}},{"id":1516584,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CEO"}}],"security":"Common Stock","published_at":"2024-05-15T22:10:22.000Z","date":"2024-05-15","kind":"sale","planned":true,"acquired":false,"shares":295,"price":980.64,"value":289288.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 5, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents volume-weighted average price of sales of 295 shares of Company stock on May 15, 2024 at prices ranging from $980.17 to $980.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price."}],"balance_after":400041,"source":{"system":"sec-edgar","filing":"0001883850-24-000022","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385024000022/edgardoc.xml","form_type":"4"}},{"id":1516583,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CEO"}}],"security":"Common Stock","published_at":"2024-05-15T22:10:22.000Z","date":"2024-05-15","kind":"sale","planned":true,"acquired":false,"shares":7864,"price":979.05,"value":7699249.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 5, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents volume-weighted average price of sales of 7,864 shares of Company stock on May 15, 2024 at prices ranging from $979.00 to $979.50. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price."}],"balance_after":400336,"source":{"system":"sec-edgar","filing":"0001883850-24-000022","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385024000022/edgardoc.xml","form_type":"4"}},{"id":1516582,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CEO"}}],"security":"Common Stock","published_at":"2024-05-15T22:10:22.000Z","date":"2024-05-14","kind":"sale","planned":true,"acquired":false,"shares":2302,"price":980.1,"value":2256190.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 5, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents volume-weighted average price of sales of 2,302 shares of Company stock on May 14, 2024 at prices ranging from $980.00 to $980.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 14, 2024 at each separate price."}],"balance_after":408200,"source":{"system":"sec-edgar","filing":"0001883850-24-000022","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385024000022/edgardoc.xml","form_type":"4"}},{"id":1516581,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CEO"}}],"security":"Common Stock","published_at":"2024-05-15T22:10:22.000Z","date":"2024-05-14","kind":"sale","planned":true,"acquired":false,"shares":22698,"price":979.16,"value":22224973.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 5, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents volume-weighted average price of sales of 22,698 shares of Company stock on May 14, 2024 at prices ranging from $979.00 to $979.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 14, 2024 at each separate price."}],"balance_after":410502,"source":{"system":"sec-edgar","filing":"0001883850-24-000022","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385024000022/edgardoc.xml","form_type":"4"}},{"id":1516580,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CEO"}}],"security":"Common Stock","published_at":"2024-05-15T22:10:22.000Z","date":"2024-05-13","kind":"tax_withholding","planned":true,"acquired":false,"shares":144433,"price":976.79,"value":141080710.07,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 5, 2024."}],"balance_after":433200,"source":{"system":"sec-edgar","filing":"0001883850-24-000022","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385024000022/edgardoc.xml","form_type":"4"}},{"id":1516579,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CEO"}}],"security":"Common Stock","published_at":"2024-05-15T22:10:22.000Z","date":"2024-05-13","kind":"exercise","planned":true,"acquired":true,"shares":203204,"price":399.66,"value":81212510.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 5, 2024."}],"balance_after":577633,"source":{"system":"sec-edgar","filing":"0001883850-24-000022","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385024000022/edgardoc.xml","form_type":"4"}},{"id":1713163,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CEO"}}],"security":"2019 Performance Stock Units","published_at":"2023-12-13T21:05:34.000Z","date":"2023-12-11","kind":"exercise","planned":false,"acquired":false,"shares":25155,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On December 11, 2019, the reporting person was granted performance-based restricted stock units (\"PSUs\") representing the contingent right to receive shares of the issuer's common stock based upon the achievement of certain performance metrics related to total shareholder return (\"TSR\") over the applicable vesting period. On December 11, 2023, 25,155 PSUs (or the maximum number of PSUs eligible for vesting) vested in full and were automatically settled into an equal number of shares of the issuer's common stock based upon achievement of 75% cumulative TSR over the four-year performance period then ended."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 11, 2019, the reporting person was granted performance-based restricted stock units (\"PSUs\") representing the contingent right to receive shares of the issuer's common stock based upon the achievement of certain performance metrics related to total shareholder return (\"TSR\") over the applicable vesting period. On December 11, 2023, 25,155 PSUs (or the maximum number of PSUs eligible for vesting) vested in full and were automatically settled into an equal number of shares of the issuer's common stock based upon achievement of 75% cumulative TSR over the four-year performance period then ended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On December 11, 2019, the reporting person was granted performance-based restricted stock units (\"PSUs\") representing the contingent right to receive shares of the issuer's common stock based upon the achievement of certain performance metrics related to total shareholder return (\"TSR\") over the applicable vesting period. On December 11, 2023, 25,155 PSUs (or the maximum number of PSUs eligible for vesting) vested in full and were automatically settled into an equal number of shares of the issuer's common stock based upon achievement of 75% cumulative TSR over the four-year performance period then ended."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On December 11, 2019, the reporting person was granted performance-based restricted stock units (\"PSUs\") representing the contingent right to receive shares of the issuer's common stock based upon the achievement of certain performance metrics related to total shareholder return (\"TSR\") over the applicable vesting period. On December 11, 2023, 25,155 PSUs (or the maximum number of PSUs eligible for vesting) vested in full and were automatically settled into an equal number of shares of the issuer's common stock based upon achievement of 75% cumulative TSR over the four-year performance period then ended."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":25155},"source":{"system":"sec-edgar","filing":"0001883850-23-000094","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000094/edgardoc.xml","form_type":"4"}},{"id":1713162,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CEO"}}],"security":"Common Stock","published_at":"2023-12-13T21:05:34.000Z","date":"2023-12-11","kind":"tax_withholding","planned":false,"acquired":false,"shares":12841,"price":844.09,"value":10838959.69,"ownership":{"direct":true},"balance_after":374429,"source":{"system":"sec-edgar","filing":"0001883850-23-000094","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000094/edgardoc.xml","form_type":"4"}},{"id":1713161,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Bd. Co-Chair, President & CEO"}}],"security":"Common Stock","published_at":"2023-12-13T21:05:34.000Z","date":"2023-12-11","kind":"exercise","planned":false,"acquired":true,"shares":25155,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 11, 2019, the reporting person was granted performance-based restricted stock units (\"PSUs\") representing the contingent right to receive shares of the issuer's common stock based upon the achievement of certain performance metrics related to total shareholder return (\"TSR\") over the applicable vesting period. On December 11, 2023, 25,155 PSUs (or the maximum number of PSUs eligible for vesting) vested in full and were automatically settled into an equal number of shares of the issuer's common stock based upon achievement of 75% cumulative TSR over the four-year performance period then ended."}],"balance_after":387270,"source":{"system":"sec-edgar","filing":"0001883850-23-000094","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000094/edgardoc.xml","form_type":"4"}},{"id":1890236,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2023-05-17T20:10:08.000Z","date":"2023-05-15","kind":"gift","planned":false,"acquired":true,"shares":53807,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Trust"},"balance_after":64985,"source":{"system":"sec-edgar","filing":"0001883850-23-000069","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000069/edgardoc.xml","form_type":"4"}},{"id":1890235,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2023-05-17T20:10:08.000Z","date":"2023-05-15","kind":"gift","planned":false,"acquired":false,"shares":53807,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"2021 GRAT"},"balance_after":0,"source":{"system":"sec-edgar","filing":"0001883850-23-000069","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000069/edgardoc.xml","form_type":"4"}},{"id":2301883,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2022-04-07T20:04:19.000Z","date":"2022-04-06","kind":"sale","acquired":false,"shares":2653,"price":710.04,"value":1883736.12,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents volume-weighted average price of sales of 2,653 shares of Company stock on April 6, 2022 at prices ranging from $710.00 to $710.13. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 6, 2022 at each separate price."}],"balance_after":11178,"source":{"system":"sec-edgar","filing":"0001883850-22-000038","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000038/edgardoc.xml","form_type":"4"}},{"id":2301882,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2022-04-07T20:04:19.000Z","date":"2022-04-05","kind":"sale","acquired":false,"shares":4461,"price":710.05,"value":3167533.05,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents volume-weighted average price of sales of 4,461 shares of Company stock on April 5, 2022 at prices ranging from $710.00 to $710.22. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 5, 2022 at each separate price."}],"balance_after":13831,"source":{"system":"sec-edgar","filing":"0001883850-22-000038","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000038/edgardoc.xml","form_type":"4"}},{"id":2309784,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2022-04-04T20:03:48.000Z","date":"2022-03-31","kind":"sale","acquired":false,"shares":2886,"price":710.01,"value":2049088.86,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents volume-weighted average price of sales of 2,886 shares of Company stock on March 31, 2022 at prices ranging from $710.00 to $710.10. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 31, 2022 at each separate price."}],"balance_after":18292,"source":{"system":"sec-edgar","filing":"0001883850-22-000036","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000036/edgardoc.xml","form_type":"4"}},{"id":2503700,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2021-11-19T22:50:44.000Z","date":"2021-11-19","kind":"exercise","acquired":false,"shares":239063,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award vests in four equal annual installments, commencing one year after the date of grant."}],"balance_after":0,"derivative":{"exercise_price":270.43,"expiration_date":"2023-12-13","underlying":"Common Stock","underlying_shares":239063},"source":{"system":"sec-edgar","filing":"0001883850-21-000009","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385021000009/edgardoc.xml","form_type":"4"}},{"id":2503699,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2021-11-19T22:50:44.000Z","date":"2021-11-19","kind":"exercise","acquired":false,"shares":281250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award vests in four equal annual installments, commencing one year after the date of grant."}],"balance_after":0,"derivative":{"exercise_price":179.13,"expiration_date":"2022-12-14","underlying":"Common Stock","underlying_shares":281250},"source":{"system":"sec-edgar","filing":"0001883850-21-000009","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385021000009/edgardoc.xml","form_type":"4"}},{"id":2503698,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-11-19T22:50:44.000Z","date":"2021-11-19","kind":"tax_withholding","acquired":false,"shares":185646,"price":651.96,"value":121033766.16,"ownership":{"direct":true},"balance_after":465922,"source":{"system":"sec-edgar","filing":"0001883850-21-000009","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385021000009/edgardoc.xml","form_type":"4"}},{"id":2503697,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-11-19T22:50:44.000Z","date":"2021-11-19","kind":"exercise","acquired":true,"shares":281250,"price":179.13,"value":50380312.5,"ownership":{"direct":true},"balance_after":651568,"source":{"system":"sec-edgar","filing":"0001883850-21-000009","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385021000009/edgardoc.xml","form_type":"4"}},{"id":2503696,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-11-19T22:50:44.000Z","date":"2021-11-19","kind":"tax_withholding","acquired":false,"shares":173491,"price":651.96,"value":113109192.36,"ownership":{"direct":true},"balance_after":370318,"source":{"system":"sec-edgar","filing":"0001883850-21-000009","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385021000009/edgardoc.xml","form_type":"4"}},{"id":2503695,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-11-19T22:50:44.000Z","date":"2021-11-19","kind":"exercise","acquired":true,"shares":239063,"price":270.43,"value":64649807.09,"ownership":{"direct":true},"balance_after":543809,"source":{"system":"sec-edgar","filing":"0001883850-21-000009","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385021000009/edgardoc.xml","form_type":"4"}},{"id":2595477,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-08-20T20:02:05.000Z","date":"2021-08-19","kind":"sale","acquired":false,"shares":10000,"price":660.03,"value":6600300.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents volume-weighted average price of sales of 10,000 shares of Company stock on August 19, 2021 at prices ranging from $660.00 to $660.13. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 19, 2021 at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held in a trust for the benefit of the reporting person's family members. The reporting person's spouse is a trustee of the trust."}],"balance_after":21178,"source":{"system":"sec-edgar","filing":"0001708138-21-000064","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000064/edgardoc.xml","form_type":"4"}},{"id":2595476,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-08-20T20:02:05.000Z","date":"2021-08-18","kind":"sale","acquired":false,"shares":200000,"price":650.03,"value":130006000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents volume-weighted average price of sales of 200,000 shares of Company stock on August 18, 2021 at prices ranging from $650.00 to $650.63. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 18, 2021 at each separate price."}],"balance_after":304746,"source":{"system":"sec-edgar","filing":"0001708138-21-000064","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000064/edgardoc.xml","form_type":"4"}},{"id":2601282,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-08-17T20:42:28.000Z","date":"2021-08-16","kind":"sale","acquired":false,"shares":303,"price":629.54,"value":190750.62,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F17","text":"Represents volume-weighted average price of sales of 303 shares of Company stock on August 16, 2021 at prices ranging from $629.18 to $629.86. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 16, 2021 at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held in a trust for the benefit of the reporting person's family members. The reporting person's spouse is a trustee of the trust."}],"balance_after":31178,"source":{"system":"sec-edgar","filing":"0001708138-21-000058","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000058/edgardoc.xml","form_type":"4"}},{"id":2601281,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-08-17T20:42:28.000Z","date":"2021-08-16","kind":"sale","acquired":false,"shares":675,"price":628.41,"value":424176.75,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F16","text":"Represents volume-weighted average price of sales of 675 shares of Company stock on August 16, 2021 at prices ranging from $628.03 to $628.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 16, 2021 at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held in a trust for the benefit of the reporting person's family members. The reporting person's spouse is a trustee of the trust."}],"balance_after":31481,"source":{"system":"sec-edgar","filing":"0001708138-21-000058","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000058/edgardoc.xml","form_type":"4"}},{"id":2601280,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-08-17T20:42:28.000Z","date":"2021-08-16","kind":"sale","acquired":false,"shares":1111,"price":627.51,"value":697163.61,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F15","text":"Represents volume-weighted average price of sales of 1,111 shares of Company stock on August 16, 2021 at prices ranging from $627.02 to $627.82. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 16, 2021 at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held in a trust for the benefit of the reporting person's family members. The reporting person's spouse is a trustee of the trust."}],"balance_after":32156,"source":{"system":"sec-edgar","filing":"0001708138-21-000058","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000058/edgardoc.xml","form_type":"4"}},{"id":2601279,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-08-17T20:42:28.000Z","date":"2021-08-16","kind":"sale","acquired":false,"shares":295,"price":626.15,"value":184714.25,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F14","text":"Represents volume-weighted average price of sales of 295 shares of Company stock on August 16, 2021 at prices ranging from $626.04 to $626.63. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 16, 2021 at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held in a trust for the benefit of the reporting person's family members. The reporting person's spouse is a trustee of the trust."}],"balance_after":33267,"source":{"system":"sec-edgar","filing":"0001708138-21-000058","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000058/edgardoc.xml","form_type":"4"}},{"id":2601278,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-08-17T20:42:28.000Z","date":"2021-08-16","kind":"sale","acquired":false,"shares":1355,"price":625.19,"value":847132.45,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"Represents volume-weighted average price of sales of 1,355 shares of Company stock on August 16, 2021 at prices ranging from $625.01 to $625.88. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 16, 2021 at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held in a trust for the benefit of the reporting person's family members. The reporting person's spouse is a trustee of the trust."}],"balance_after":33562,"source":{"system":"sec-edgar","filing":"0001708138-21-000058","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000058/edgardoc.xml","form_type":"4"}},{"id":2601277,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-08-17T20:42:28.000Z","date":"2021-08-16","kind":"sale","acquired":false,"shares":1862,"price":624.42,"value":1162670.04,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"Represents volume-weighted average price of sales of 1,862 shares of Company stock on August 16, 2021 at prices ranging from $624.00 to $624.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 16, 2021 at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held in a trust for the benefit of the reporting person's family members. The reporting person's spouse is a trustee of the trust."}],"balance_after":34917,"source":{"system":"sec-edgar","filing":"0001708138-21-000058","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000058/edgardoc.xml","form_type":"4"}},{"id":2601276,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-08-17T20:42:28.000Z","date":"2021-08-16","kind":"sale","acquired":false,"shares":2393,"price":623.66,"value":1492418.38,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"Represents volume-weighted average price of sales of 2,393 shares of Company stock on August 16, 2021 at prices ranging from $623.08 to $623.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 16, 2021 at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held in a trust for the benefit of the reporting person's family members. The reporting person's spouse is a trustee of the trust."}],"balance_after":36779,"source":{"system":"sec-edgar","filing":"0001708138-21-000058","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000058/edgardoc.xml","form_type":"4"}},{"id":2601275,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-08-17T20:42:28.000Z","date":"2021-08-16","kind":"sale","acquired":false,"shares":924,"price":622.44,"value":575134.56,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Represents volume-weighted average price of sales of 924 shares of Company stock on August 16, 2021 at prices ranging from $622.00 to $622.84. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 16, 2021 at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held in a trust for the benefit of the reporting person's family members. The reporting person's spouse is a trustee of the trust."}],"balance_after":39172,"source":{"system":"sec-edgar","filing":"0001708138-21-000058","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000058/edgardoc.xml","form_type":"4"}},{"id":2601274,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-08-17T20:42:28.000Z","date":"2021-08-16","kind":"sale","acquired":false,"shares":287,"price":621.76,"value":178445.12,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Represents volume-weighted average price of sales of 287 shares of Company stock on August 16, 2021 at prices ranging from $621.25 to $621.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 16, 2021 at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held in a trust for the benefit of the reporting person's family members. The reporting person's spouse is a trustee of the trust."}],"balance_after":40096,"source":{"system":"sec-edgar","filing":"0001708138-21-000058","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000058/edgardoc.xml","form_type":"4"}},{"id":2601273,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-08-17T20:42:28.000Z","date":"2021-08-16","kind":"sale","acquired":false,"shares":96,"price":620.36,"value":59554.56,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Represents volume-weighted average price of sales of 96 shares of Company stock on August 16, 2021 at prices ranging from $620.35 to $620.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 16, 2021 at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held in a trust for the benefit of the reporting person's family members. The reporting person's spouse is a trustee of the trust."}],"balance_after":40383,"source":{"system":"sec-edgar","filing":"0001708138-21-000058","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000058/edgardoc.xml","form_type":"4"}},{"id":2601272,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-08-17T20:42:28.000Z","date":"2021-08-16","kind":"sale","acquired":false,"shares":34,"price":619.83,"value":21074.22,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents volume-weighted average price of sales of 34 shares of Company stock on August 16, 2021 at prices ranging from $619.67 to $619.84. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 16, 2021 at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held in a trust for the benefit of the reporting person's family members. The reporting person's spouse is a trustee of the trust."}],"balance_after":40479,"source":{"system":"sec-edgar","filing":"0001708138-21-000058","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000058/edgardoc.xml","form_type":"4"}},{"id":2601271,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-08-17T20:42:28.000Z","date":"2021-08-16","kind":"sale","acquired":false,"shares":90,"price":618.82,"value":55693.8,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents volume-weighted average price of sales of 90 shares of Company stock on August 16, 2021 at prices ranging from $618.13 to $618.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 16, 2021 at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held in a trust for the benefit of the reporting person's family members. The reporting person's spouse is a trustee of the trust."}],"balance_after":40513,"source":{"system":"sec-edgar","filing":"0001708138-21-000058","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000058/edgardoc.xml","form_type":"4"}},{"id":2601270,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-08-17T20:42:28.000Z","date":"2021-08-16","kind":"sale","acquired":false,"shares":258,"price":617.79,"value":159389.82,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents volume-weighted average price of sales of 258 shares of Company stock on August 16, 2021 at prices ranging from $617.56 to $617.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 16, 2021 at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held in a trust for the benefit of the reporting person's family members. The reporting person's spouse is a trustee of the trust."}],"balance_after":40603,"source":{"system":"sec-edgar","filing":"0001708138-21-000058","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000058/edgardoc.xml","form_type":"4"}},{"id":2601269,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-08-17T20:42:28.000Z","date":"2021-08-16","kind":"sale","acquired":false,"shares":146,"price":616.7,"value":90038.2,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents volume-weighted average price of sales of 146 shares of Company stock on August 16, 2021 at prices ranging from $616.66 to $616.73. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 16, 2021 at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held in a trust for the benefit of the reporting person's family members. The reporting person's spouse is a trustee of the trust."}],"balance_after":40861,"source":{"system":"sec-edgar","filing":"0001708138-21-000058","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000058/edgardoc.xml","form_type":"4"}},{"id":2601268,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-08-17T20:42:28.000Z","date":"2021-08-16","kind":"sale","acquired":false,"shares":171,"price":615.54,"value":105257.34,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents volume-weighted average price of sales of 171 shares of Company stock on August 16, 2021 at prices ranging from $615.35 to $615.79. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 16, 2021 at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held in a trust for the benefit of the reporting person's family members. The reporting person's spouse is a trustee of the trust."}],"balance_after":41007,"source":{"system":"sec-edgar","filing":"0001708138-21-000058","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000058/edgardoc.xml","form_type":"4"}},{"id":2609233,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2021-08-10T21:05:59.000Z","date":"2021-08-06","kind":"exercise","acquired":false,"shares":160000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"With respect to 240,000 underlying shares (of which 0 remain outstanding), the option became exercisable on December 31, 2014, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2014. With respect to 160,000 underlying shares (of which 0 remain outstanding), the stock option award vested in four equal annual installments, commencing one year after the date of grant."}],"balance_after":0,"derivative":{"exercise_price":52.03,"expiration_date":"2021-12-16","underlying":"Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0001708138-21-000048","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000048/edgardoc.xml","form_type":"4"}},{"id":2609232,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2021-08-10T21:05:59.000Z","date":"2021-08-06","kind":"exercise","acquired":false,"shares":240000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"With respect to 240,000 underlying shares (of which 0 remain outstanding), the option became exercisable on December 31, 2014, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2014. With respect to 160,000 underlying shares (of which 0 remain outstanding), the stock option award vested in four equal annual installments, commencing one year after the date of grant."}],"balance_after":160000,"derivative":{"exercise_price":52.03,"expiration_date":"2021-12-16","underlying":"Common Stock","underlying_shares":240000},"source":{"system":"sec-edgar","filing":"0001708138-21-000048","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000048/edgardoc.xml","form_type":"4"}},{"id":2609231,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-08-10T21:05:59.000Z","date":"2021-05-19","kind":"gift","acquired":false,"shares":41178,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"by 2019 GRAT"},"balance_after":0,"source":{"system":"sec-edgar","filing":"0001708138-21-000048","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000048/edgardoc.xml","form_type":"4"}},{"id":2609230,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-08-10T21:05:59.000Z","date":"2021-05-19","kind":"gift","acquired":true,"shares":41178,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held in a trust for the benefit of the reporting person's family members. The reporting person's spouse is a trustee of the trust."}],"balance_after":41178,"source":{"system":"sec-edgar","filing":"0001708138-21-000048","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000048/edgardoc.xml","form_type":"4"}},{"id":2609229,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-08-10T21:05:59.000Z","date":"2021-08-06","kind":"tax_withholding","acquired":false,"shares":91430,"price":607.51,"value":55544639.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":504746,"source":{"system":"sec-edgar","filing":"0001708138-21-000048","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000048/edgardoc.xml","form_type":"4"}},{"id":2609228,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-08-10T21:05:59.000Z","date":"2021-08-06","kind":"exercise","acquired":true,"shares":160000,"price":52.03,"value":8324800.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":596176,"source":{"system":"sec-edgar","filing":"0001708138-21-000048","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000048/edgardoc.xml","form_type":"4"}},{"id":2609227,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-08-10T21:05:59.000Z","date":"2021-08-06","kind":"tax_withholding","acquired":false,"shares":137145,"price":607.51,"value":83316958.95,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":436176,"source":{"system":"sec-edgar","filing":"0001708138-21-000048","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000048/edgardoc.xml","form_type":"4"}},{"id":2609226,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-08-10T21:05:59.000Z","date":"2021-08-06","kind":"exercise","acquired":true,"shares":240000,"price":52.03,"value":12487200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":573321,"source":{"system":"sec-edgar","filing":"0001708138-21-000048","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000048/edgardoc.xml","form_type":"4"}},{"id":2923366,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Performance Stock Units","published_at":"2021-01-05T21:04:01.000Z","date":"2020-12-31","kind":"grant","acquired":true,"shares":620270,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance restricted stock unit (\"PSU\") represents a contingent right to receive one share of Company stock. The amount reported is the maximum number of PSUs that may be earned upon achievement of certain total shareholder return (\"TSR\") goals derived from compound annual growth rates of 5.6% to 19.2% over a five-year performance period ending on December 31, 2025 (or in some cases at earlier times). Between 50% and 250% of the target number of 248,108 PSUs may be earned upon achievement of such TSR goals but shall only vest at the end of the five-year performance period if the reporting person's service to the Company continues through such date, except in certain limited cases (such as if service to the Company is terminated by the Company without cause or in case of a change in control (\"CIC\")). Earned PSUs are subject to a mandatory holding period of three years after vesting, which ends early upon the reporting person's death or disability or a CIC."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each performance restricted stock unit (\"PSU\") represents a contingent right to receive one share of Company stock. The amount reported is the maximum number of PSUs that may be earned upon achievement of certain total shareholder return (\"TSR\") goals derived from compound annual growth rates of 5.6% to 19.2% over a five-year performance period ending on December 31, 2025 (or in some cases at earlier times). Between 50% and 250% of the target number of 248,108 PSUs may be earned upon achievement of such TSR goals but shall only vest at the end of the five-year performance period if the reporting person's service to the Company continues through such date, except in certain limited cases (such as if service to the Company is terminated by the Company without cause or in case of a change in control (\"CIC\")). Earned PSUs are subject to a mandatory holding period of three years after vesting, which ends early upon the reporting person's death or disability or a CIC."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each performance restricted stock unit (\"PSU\") represents a contingent right to receive one share of Company stock. The amount reported is the maximum number of PSUs that may be earned upon achievement of certain total shareholder return (\"TSR\") goals derived from compound annual growth rates of 5.6% to 19.2% over a five-year performance period ending on December 31, 2025 (or in some cases at earlier times). Between 50% and 250% of the target number of 248,108 PSUs may be earned upon achievement of such TSR goals but shall only vest at the end of the five-year performance period if the reporting person's service to the Company continues through such date, except in certain limited cases (such as if service to the Company is terminated by the Company without cause or in case of a change in control (\"CIC\")). Earned PSUs are subject to a mandatory holding period of three years after vesting, which ends early upon the reporting person's death or disability or a CIC."}],"balance_after":620270,"derivative":{"underlying":"Common Stock","underlying_shares":620270},"source":{"system":"sec-edgar","filing":"0001104659-21-000901","document":"tm211598-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000110465921000901/tm211598-1_4seq1.xml","form_type":"4"}},{"id":3151650,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2020-05-14T01:01:15.000Z","date":"2020-05-11","kind":"exercise","acquired":false,"shares":187500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F23","text":"With respect to 125,000 underlying shares (of which 0 remain outstanding), the stock option award vested in four equal annual installments, commencing one year after the date of grant. With respect to 187,500 underlying shares (of which 0 remain outstanding), the option became exercisable on December 31, 2013, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2013."}],"balance_after":0,"derivative":{"exercise_price":30.63,"expiration_date":"2020-12-14","underlying":"Common Stock","underlying_shares":187500},"source":{"system":"sec-edgar","filing":"0001708138-20-000058","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":29,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813820000058/edgardoc.xml","form_type":"4"}},{"id":3151649,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2020-05-14T01:01:15.000Z","date":"2020-05-11","kind":"exercise","acquired":false,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F23","text":"With respect to 125,000 underlying shares (of which 0 remain outstanding), the stock option award vested in four equal annual installments, commencing one year after the date of grant. With respect to 187,500 underlying shares (of which 0 remain outstanding), the option became exercisable on December 31, 2013, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2013."}],"balance_after":187500,"derivative":{"exercise_price":30.63,"expiration_date":"2020-12-14","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001708138-20-000058","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":28,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813820000058/edgardoc.xml","form_type":"4"}},{"id":3151648,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-05-14T01:01:15.000Z","date":"2020-05-12","kind":"sale","acquired":false,"shares":638,"price":577.27,"value":368298.26,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F22","text":"Represents volume-weighted average price of sales of 638 shares of Company stock on May 12, 2020 at prices ranging from $577.15 to $577.55. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 12, 2020 at each separate price."}],"balance_after":474499,"source":{"system":"sec-edgar","filing":"0001708138-20-000058","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":25,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813820000058/edgardoc.xml","form_type":"4"}},{"id":3151647,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-05-14T01:01:15.000Z","date":"2020-05-12","kind":"sale","acquired":false,"shares":1728,"price":576.51,"value":996209.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F21","text":"Represents volume-weighted average price of sales of 1,728 shares of Company stock on May 12, 2020 at prices ranging from $576.04 to $576.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 12, 2020 at each separate price."}],"balance_after":475137,"source":{"system":"sec-edgar","filing":"0001708138-20-000058","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813820000058/edgardoc.xml","form_type":"4"}},{"id":3151646,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-05-14T01:01:15.000Z","date":"2020-05-12","kind":"sale","acquired":false,"shares":2196,"price":575.48,"value":1263754.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F20","text":"Represents volume-weighted average price of sales of 2,196 shares of Company stock on May 12, 2020 at prices ranging from $575.04 to $575.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 12, 2020 at each separate price."}],"balance_after":476865,"source":{"system":"sec-edgar","filing":"0001708138-20-000058","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813820000058/edgardoc.xml","form_type":"4"}},{"id":3151645,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-05-14T01:01:15.000Z","date":"2020-05-12","kind":"sale","acquired":false,"shares":4390,"price":574.59,"value":2522450.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F19","text":"Represents volume-weighted average price of sales of 4,390 shares of Company stock on May 12, 2020 at prices ranging from $574.17 to $574.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 12, 2020 at each separate price."}],"balance_after":479061,"source":{"system":"sec-edgar","filing":"0001708138-20-000058","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813820000058/edgardoc.xml","form_type":"4"}},{"id":3151644,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-05-14T01:01:15.000Z","date":"2020-05-12","kind":"sale","acquired":false,"shares":10014,"price":573.27,"value":5740725.78,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F18","text":"Represents volume-weighted average price of sales of 10,014 shares of Company stock on May 12, 2020 at prices ranging from $573.00 to $573.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 12, 2020 at each separate price."}],"balance_after":483451,"source":{"system":"sec-edgar","filing":"0001708138-20-000058","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813820000058/edgardoc.xml","form_type":"4"}},{"id":3151643,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-05-14T01:01:15.000Z","date":"2020-05-12","kind":"sale","acquired":false,"shares":19984,"price":572.47,"value":11440240.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F17","text":"Represents volume-weighted average price of sales of 19,984 shares of Company stock on May 12, 2020 at prices ranging from $572.00 to $572.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 12, 2020 at each separate price."}],"balance_after":493465,"source":{"system":"sec-edgar","filing":"0001708138-20-000058","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813820000058/edgardoc.xml","form_type":"4"}},{"id":3151642,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-05-14T01:01:15.000Z","date":"2020-05-12","kind":"sale","acquired":false,"shares":15542,"price":571.49,"value":8882097.58,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F16","text":"Represents volume-weighted average price of sales of 15,542 shares of Company stock on May 12, 2020 at prices ranging from $571.00 to $571.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 12, 2020 at each separate price."}],"balance_after":513449,"source":{"system":"sec-edgar","filing":"0001708138-20-000058","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813820000058/edgardoc.xml","form_type":"4"}},{"id":3151641,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-05-14T01:01:15.000Z","date":"2020-05-12","kind":"sale","acquired":false,"shares":20267,"price":570.49,"value":11562120.83,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F15","text":"Represents volume-weighted average price of sales of 20,267 shares of Company stock on May 12, 2020 at prices ranging from $570.01 to $570.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 12, 2020 at each separate price."}],"balance_after":528991,"source":{"system":"sec-edgar","filing":"0001708138-20-000058","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813820000058/edgardoc.xml","form_type":"4"}},{"id":3151640,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-05-14T01:01:15.000Z","date":"2020-05-12","kind":"sale","acquired":false,"shares":19982,"price":569.52,"value":11380148.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F14","text":"Represents volume-weighted average price of sales of 19,982 shares of Company stock on May 12, 2020 at prices ranging from $569.00 to $569.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 12, 2020 at each separate price."}],"balance_after":549258,"source":{"system":"sec-edgar","filing":"0001708138-20-000058","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813820000058/edgardoc.xml","form_type":"4"}},{"id":3151639,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-05-14T01:01:15.000Z","date":"2020-05-12","kind":"sale","acquired":false,"shares":18021,"price":568.58,"value":10246380.18,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"Represents volume-weighted average price of sales of 18,021 shares of Company stock on May 12, 2020 at prices ranging from $568.00 to $568.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 12, 2020 at each separate price."}],"balance_after":569240,"source":{"system":"sec-edgar","filing":"0001708138-20-000058","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813820000058/edgardoc.xml","form_type":"4"}},{"id":3151638,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-05-14T01:01:15.000Z","date":"2020-05-12","kind":"sale","acquired":false,"shares":9359,"price":567.57,"value":5311887.63,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"Represents volume-weighted average price of sales of 9,359 shares of Company stock on May 12, 2020 at prices ranging from $567.00 to $567.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 12, 2020 at each separate price."}],"balance_after":587261,"source":{"system":"sec-edgar","filing":"0001708138-20-000058","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813820000058/edgardoc.xml","form_type":"4"}},{"id":3151637,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-05-14T01:01:15.000Z","date":"2020-05-12","kind":"sale","acquired":false,"shares":5810,"price":566.51,"value":3291423.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"Represents volume-weighted average price of sales of 5,810 shares of Company stock on May 12, 2020 at prices ranging from $566.00 to $566.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 12, 2020 at each separate price."}],"balance_after":596620,"source":{"system":"sec-edgar","filing":"0001708138-20-000058","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813820000058/edgardoc.xml","form_type":"4"}},{"id":3151636,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-05-14T01:01:15.000Z","date":"2020-05-12","kind":"sale","acquired":false,"shares":3032,"price":565.67,"value":1715111.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Represents volume-weighted average price of sales of 3,032 shares of Company stock on May 12, 2020 at prices ranging from $565.16 to $565.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 12, 2020 at each separate price."}],"balance_after":602430,"source":{"system":"sec-edgar","filing":"0001708138-20-000058","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813820000058/edgardoc.xml","form_type":"4"}},{"id":3151635,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-05-14T01:01:15.000Z","date":"2020-05-12","kind":"sale","acquired":false,"shares":779,"price":564.41,"value":439675.39,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Represents volume-weighted average price of sales of 779 shares of Company stock on May 12, 2020 at prices ranging from $564.01 to $564.69. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 12, 2020 at each separate price."}],"balance_after":605462,"source":{"system":"sec-edgar","filing":"0001708138-20-000058","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813820000058/edgardoc.xml","form_type":"4"}},{"id":3151634,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-05-14T01:01:15.000Z","date":"2020-05-12","kind":"sale","acquired":false,"shares":2549,"price":563.51,"value":1436386.99,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Represents volume-weighted average price of sales of 2,549 shares of Company stock on May 12, 2020 at prices ranging from $563.12 to $563.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 12, 2020 at each separate price."}],"balance_after":606241,"source":{"system":"sec-edgar","filing":"0001708138-20-000058","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813820000058/edgardoc.xml","form_type":"4"}},{"id":3151633,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-05-14T01:01:15.000Z","date":"2020-05-12","kind":"sale","acquired":false,"shares":1394,"price":562.75,"value":784473.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents volume-weighted average price of sales of 1,394 shares of Company stock on May 12, 2020 at prices ranging from $562.33 to $562.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 12, 2020 at each separate price."}],"balance_after":608790,"source":{"system":"sec-edgar","filing":"0001708138-20-000058","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813820000058/edgardoc.xml","form_type":"4"}},{"id":3151632,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-05-14T01:01:15.000Z","date":"2020-05-12","kind":"sale","acquired":false,"shares":3994,"price":561.24,"value":2241592.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents volume-weighted average price of sales of 3,994 shares of Company stock on May 12, 2020 at prices ranging from $561.00 to $561.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 12, 2020 at each separate price."}],"balance_after":610184,"source":{"system":"sec-edgar","filing":"0001708138-20-000058","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813820000058/edgardoc.xml","form_type":"4"}},{"id":3151631,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-05-14T01:01:15.000Z","date":"2020-05-12","kind":"sale","acquired":false,"shares":3391,"price":560.68,"value":1901265.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents volume-weighted average price of sales of 3,391 shares of Company stock on May 12, 2020 at prices ranging from $560.19 to $560.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 12, 2020 at each separate price."}],"balance_after":614178,"source":{"system":"sec-edgar","filing":"0001708138-20-000058","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813820000058/edgardoc.xml","form_type":"4"}},{"id":3151630,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-05-14T01:01:15.000Z","date":"2020-05-12","kind":"sale","acquired":false,"shares":1361,"price":559.52,"value":761506.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents volume-weighted average price of sales of 1,361 shares of Company stock on May 12, 2020 at prices ranging from $559.02 to $559.84. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 12, 2020 at each separate price."}],"balance_after":617569,"source":{"system":"sec-edgar","filing":"0001708138-20-000058","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813820000058/edgardoc.xml","form_type":"4"}},{"id":3151629,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-05-14T01:01:15.000Z","date":"2020-05-12","kind":"sale","acquired":false,"shares":4162,"price":558.35,"value":2323852.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents volume-weighted average price of sales of 4,162 shares of Company stock on May 12, 2020 at prices ranging from $558.00 to $558.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 12, 2020 at each separate price."}],"balance_after":618930,"source":{"system":"sec-edgar","filing":"0001708138-20-000058","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813820000058/edgardoc.xml","form_type":"4"}},{"id":3151628,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-05-14T01:01:15.000Z","date":"2020-05-12","kind":"sale","acquired":false,"shares":2329,"price":557.51,"value":1298440.79,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents volume-weighted average price of sales of 2,329 shares of Company stock on May 12, 2020 at prices ranging from $557.02 to $557.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 12, 2020 at each separate price."}],"balance_after":623092,"source":{"system":"sec-edgar","filing":"0001708138-20-000058","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813820000058/edgardoc.xml","form_type":"4"}},{"id":3151627,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-05-14T01:01:15.000Z","date":"2020-05-11","kind":"tax_withholding","acquired":false,"shares":96947,"price":571.43,"value":55398424.21,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":625421,"source":{"system":"sec-edgar","filing":"0001708138-20-000058","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813820000058/edgardoc.xml","form_type":"4"}},{"id":3151626,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-05-14T01:01:15.000Z","date":"2020-05-11","kind":"exercise","acquired":true,"shares":187500,"price":30.63,"value":5743125.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":722368,"source":{"system":"sec-edgar","filing":"0001708138-20-000058","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813820000058/edgardoc.xml","form_type":"4"}},{"id":3151625,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-05-14T01:01:15.000Z","date":"2020-05-11","kind":"tax_withholding","acquired":false,"shares":64631,"price":571.43,"value":36932092.33,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":534868,"source":{"system":"sec-edgar","filing":"0001708138-20-000058","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813820000058/edgardoc.xml","form_type":"4"}},{"id":3151624,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-05-14T01:01:15.000Z","date":"2020-05-11","kind":"exercise","acquired":true,"shares":125000,"price":30.63,"value":3828750.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":599499,"source":{"system":"sec-edgar","filing":"0001708138-20-000058","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813820000058/edgardoc.xml","form_type":"4"}},{"id":3342828,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Performance Stock Units","published_at":"2019-12-13T21:05:39.000Z","date":"2019-12-11","kind":"grant","acquired":true,"shares":25155,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each performance-based restricted stock unit (\"PSU\") represents the contingent right to receive one share of the issuer's common stock at vesting.  The amount reported reflects the maximum number of PSUs that may vest based upon the achievement of certain performance metrics related to total shareholder return over four-year and/or five-year performance periods ending on December 11, 2023 and December 11, 2024, respectively. Between 50% and 225% of the target number of PSUs (i.e., between 50% and 225% of 11,180 PSUs) may vest upon achievement of predetermined total shareholder return percentages derived from compound annual growth rates of 5% to 15% for the applicable performance period.  If none of the performance metrics are achieved at the conclusion of the performance periods, the award expires."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each performance-based restricted stock unit (\"PSU\") represents the contingent right to receive one share of the issuer's common stock at vesting.  The amount reported reflects the maximum number of PSUs that may vest based upon the achievement of certain performance metrics related to total shareholder return over four-year and/or five-year performance periods ending on December 11, 2023 and December 11, 2024, respectively. Between 50% and 225% of the target number of PSUs (i.e., between 50% and 225% of 11,180 PSUs) may vest upon achievement of predetermined total shareholder return percentages derived from compound annual growth rates of 5% to 15% for the applicable performance period.  If none of the performance metrics are achieved at the conclusion of the performance periods, the award expires."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each performance-based restricted stock unit (\"PSU\") represents the contingent right to receive one share of the issuer's common stock at vesting.  The amount reported reflects the maximum number of PSUs that may vest based upon the achievement of certain performance metrics related to total shareholder return over four-year and/or five-year performance periods ending on December 11, 2023 and December 11, 2024, respectively. Between 50% and 225% of the target number of PSUs (i.e., between 50% and 225% of 11,180 PSUs) may vest upon achievement of predetermined total shareholder return percentages derived from compound annual growth rates of 5% to 15% for the applicable performance period.  If none of the performance metrics are achieved at the conclusion of the performance periods, the award expires."}],"balance_after":25155,"derivative":{"underlying":"Common Stock","underlying_shares":25155},"source":{"system":"sec-edgar","filing":"0001237899-19-000031","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/872589/000123789919000031/edgardoc.xml","form_type":"4"}},{"id":3342827,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70475,"kind":"person","name":"SCHLEIFER LEONARD S","position":1,"cik":"0001218629","reported_name":"SCHLEIFER LEONARD S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2019-12-13T21:05:39.000Z","date":"2019-12-11","kind":"grant","acquired":true,"shares":81278,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award vests in four equal annual installments, commencing one year after the date of grant."}],"balance_after":81278,"derivative":{"exercise_price":372.46,"expiration_date":"2029-12-11","underlying":"Common Stock","underlying_shares":81278},"source":{"system":"sec-edgar","filing":"0001237899-19-000031","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/872589/000123789919000031/edgardoc.xml","form_type":"4"}}],"next_cursor":"2019-12-13T21:05:39.000000Z,3342827"}